CONTINUOUS SUBCUTANEOUS INFUSION OF KETOROLAC IN CANCER NEUROPATHIC PAIN UNRESPONSIVE TO OPIOID AND ADJUVANT DRUGS - A CASE-REPORT

Ketorolac is a new non-steroidal anti-inflammatory drug (NSAID) having a potent nonopioid analgesic activity. Administered by continuous sub cutaneous infusion (CSI), its analgesic efficacy has been documented i n the treatment of somatic and visceral cancer pain whilst it has been shown to be ineffective in the treatment of neuropathic pain, Here is a description of a cancer patient with neuropathic pain unresponsive to anticonvulsant or antidepressant drugs administered in association or not with oral opioids but who was successfully treated with ketorol ac alone via CSI, furthermore, the analgesia lasted over 75 days of tr eatment without any significant renal and gastric side effects.